PT  - JOURNAL ARTICLE
AU  - Gan, Yichuan
AU  - Du, Lingyan
AU  - Faleti, Oluwasijibomi Damola
AU  - Huang, Jing
AU  - Xiao, Gang
AU  - Lyu, Xiaoming
TI  - Sample Pooling as a Strategy of SARS-COV-2 Nucleic Acid Screening Increases the False-negative Rate
AID  - 10.1101/2020.05.18.20106138
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.18.20106138
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.18.20106138.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.18.20106138.full
AB  - Identification of less costly and accurate methods for monitoring novel coronavirus disease 2019 (CoViD-19) transmission has attracted much interest in recent times. Here, we evaluated a pooling method to determine if this could improve screening efficiency and reduce costs while maintaining accuracy in Guangzhou, China. We evaluated 8097 throat swap samples collected from individuals who came for a health check-up or fever clinic in The Third Affiliated Hospital, Southern Medical University between March 4, 2020 and April 26, 2020. Samples were screened for CoViD-19 infection using the WHO-approved quantitative reverse transcription PCR (RT-qPCR) primers. The positive samples were classified into two groups (high or low) based on viral load in accordance with the CT value of COVID-19 RT-qPCR results. Each positive RNA samples were mixed with COVID-19 negative RNA or ddH2O to form RNA pools. Samples with high viral load could be detected in pool negative samples (up to 1/1000 dilution fold). In contrast, the detection of RNA sample from positive patients with low viral load in a pool was difficult and not repeatable. Our results show that the COVID-19 viral load significantly influences in pooling efficacy. COVID-19 has distinct viral load profile which depends on the timeline of infection. Thus, application of pooling for infection surveillance may lead to false negatives and hamper infection control efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from National Natural Science Foundation of China (No. 81502335), Hong Kong Scholars Program (XJ2017-146), Natural Science Foundation of Guangdong Province (No.2020A1515010081). Science and Technology Program of Guangzhou, China (No. 201704020127).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is available.